Measles nucleoprotein Antibody

Product Discontinued

Measles nucleoprotein Antibody Summary

• Immunogen: Recombinant full length protein.
• Specificity: Reacts with specifically with 60 kDa measles nucleoprotein
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Purity: Unpurified

Applications/Dilutions

• Dilutions:
  • ELISA 1:2000-1:10000
  • Immunocytochemistry/ Immunofluorescence 1:100 - 1:500
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin
  • Western Blot 1:200-1:1000
• Application Notes: Use in IHC reported in scientific literature (PMID: 29367943). Use in IHC-P reported in multiple pieces of scientific literature.
• Theoretical MW: 60 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reactivity Notes

Reacts with Measles virus (Paramyxovirus). Human reactivity reported in scientific literature (PMID: 24646176). Mouse reactivity reported in scientific literature ( 23380817).

Packaging, Storage & Formulations

• Storage: Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
• Buffer: Antiserum
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: Unpurified
• Reconstitution Instructions: Lyophilized powder, reconstituted in distilled water.

Alternate Names for Measles nucleoprotein Antibody

• Measles nucleocapsid protein
• N
• NP protein
• NP
• Nucleocapsid protein
• Nucleoprotein
• Protein N

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Rubeola (Measles) Nucleoprotein Antibody (NB100-1856)(8)

Publications using NB100-1856

• Lal S, Raffel C. Using Cystine knot Proteins as a Novel Approach to Retarget Oncolytic Measles Virus. Molecular Therapy-Oncolytics. [PMID: 29367943] (IF/IHC, Human)
• Studebaker AW, Hutzen B, Pierson CR et al. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors Neuro-oncology 2015-04-02 [PMID: 25838138] (IHC-P, Human)
• Rennick LJ, de Vries RD, Carsillo TJ et al. Live-attenuated measles virus vaccine targets dendritic cells and macrophages in the muscle of non-human primates. J. Virol. 2014-12-03 [PMID: 25473055] (IHC-P, Virus)
  
  Details:
  Rubeola (Measles) Nucleoprotein antibody used for IHC-P with dual indirect immunofluorescence detection on formalin-fixed muscle tissue sections from macaque/monkey (MV-seronegative cynomolgus macaques /Macaca fascicularis) infected with rMVEZEGFP(3) (animal EZ26 at 3 d.p.i.). Immunostaining images are shown in FIG 4C and 4D.
• Hutzen Brian, Bid Hemant Kumar, Houghton Peter J et al. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin. BMC Cancer. 2014-03-19 [PMID: 24646176] (IHC-P, Human, Virus)
• Friedrich K, Hanauer JR, Prufer S et al. DARPin-targeting of Measles Virus: Unique Bispecificity, Effective Oncolysis, and Enhanced Safety. Mol Ther 2013-02-05 [PMID: 23380817] (IHC-P, Mouse)
• Hutzen B, Pierson CR, Russell SJ et al. Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine BMC Cancer 2012-11-07 [PMID: 23134812] (IF/IHC, Mouse)
• Studebaker AW, Hutzen B, Pierson CR, Russell SJ, Galanis E, Raffel C. Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma. Neuro Oncol. 2012-02-03 [PMID: 22307474]
• Iwasaki M, Takeda M, Shirogane Y et al. The Matrix Protein of Measles Virus Regulates Viral RNA Synthesis Assembly by Interacting with the Nucleocapsid Protein. J Virol :JVI01056-01009. 2009-01-01 [PMID: 19656884]